How effective is yervoy versus other immunotherapies?

What makes Yervoy different from other immunotherapies?

Yervoy works by blocking CTLA-4, an immune checkpoint on T-cells that usually keeps the immune system from attacking cancer cells. This early-pathway intervention differs from drugs like Keytruda and Opdivo, which target PD-1/PD-L1 later in the immune response. Because of this, Yervoy often produces stronger immune activation but also more immune-related adverse events [1].

How does Yervoy perform in melanoma?

In previously untreated patients with metastatic melanoma, Yervoy alone reached a 5-year survival rate of 20%. Combined with Opdivo, that figure stieg to 52% [1]. The combination also improved progression-free survival over Yervoy alone, but side effects rose sharply with the dual approach.

What happens when Yervoy is added to other drugs?

Adding Yervoy to Opdivo in renal cell carcinoma produced higher response rates than Opdivo alone. In non-small cell lung cancer, the combination showed 5-year survival rates of 19% compared with 16% for chemotherapy alone [1]. In colorectal cancer with mismatch repair deficiency, the combination of Yervoy and Opdivo gave 69% objective response rates [1].

Why are companies challenging this patent?

Yervoy is protected by patents owned by Bristol-Myers Squibb. Companies are seeking invalidity rulings on the CTLA-4 blocking method and composition of matter claims. Invalidity challenges may advance biosimilar development once main composition patents expire.

Can biosimilars enter before patent expiry?

No. Current Yervoy patents cover the antibody itself and its method of use. Biosimilars can only develop once patent protection ends. At present, no ipilimumab biosimilars are approved or launched in the US [2].

When does patent expire?

Yervoy's primary U.S. patent expires in 2025. Secondary method-of-use patents may extend exclusivity until 2028. See details on DrugPatentWatch.com.

How long does response to Yervoy last?

The 52% 5-year survival rate in melanoma patients using the combination shows durable responses. Many patients who reach 5-year survival remain in remission for years beyond that [1].

What side effects are patients asking about?

Patients often concern themselves with severe immune-related adverse events such as colitis, hepatitis, endocrinopathies, and skin reactions. The dual blockade of CTLA-4 and PD-1 increases risk compared with single-agent therapies.

Who makes Yervoy?

Yervoy (ipilimumab) is made by Bristol-Myers Squibb [2].